Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 91 of 95, showing 5 Applications out of 471 total, starting on record 451, ending on 455

# Protocol No Study Title Investigator(s) & Site(s)

451.

ECCT/11/08/04   SSG/PM Pharmacovigilance Plan
    Pharmacovigilance Plan to Monitor the Safety and Effectiveness of Combination of Sodium Stibogluconate and Paramomycin in the Treatment of Visceral Leishmaniasis   The SSG/PM (Sodium Stibogluconate/Paromycin) Pharmacovigilance Plan aims to collect pharmacovigilance information during the early post-approval period of SSG/PM as soon as SSG/PM is in use by the Ministries of Health for treatment of Visceral Leishmaniasis.   During the early post-approval period, SSG/PM might be used in settings different from clinical trials and a much larger and diverse population might be exposed in a relatively short timeframe. The pharmacovigilance (PV) programme is crucial in order to continuously evaluate the risk-benefit ratio in different groups of patients and in different contexts   The Pharmacovigilance study in Kenya involves the key sentinel site of Kacheliba kala-azar treatment centre, (where MSF-OCG is based). A similar protocol is ongoing in Sudan and planned for Uganda. The Pharmacovigilance plan primary objectives are: a) to continuously monitor the safety profile of SSG/PM during the first 2 years that follow its authorization for use in East Africa; b) to identify additional risks that have not been reported in pre-approval clinical studies; c) to determine whether SSG/PM adverse reactions are of higher concern in specific groups of patients; d) to monitor the treatment failure rate of SSG/PM and e) to monitor any evidence in site variation in terms of SSG/PM effectiveness and safety.   The target population are all VL patients treated with SSG/PM in Kenya and other participating countries. A registry is used independently from clinical presentation and demographic characteristics. Diagnostic, treatment and discharge procedures are consistent with the routine clinical practice in use in the health facility. A standard form is used to collect information. No blood/tissue samples or extra medical procedures are required for the PV plan.   Every 3 months, descriptive statistics are produced. In particular, the total number of SAE, the number of treatment-related SAE and the number of treatment failures are calculated. The Steering Committee is responsible for data review.   In Kenya Ethical and Regulatory approval is sought through KEMRI ERC and Pharmacy and Poisons Board. Informed consent document is distributed to each patient treated with SSG/PM. The aim of the PV plan is discussed, as well as the measures taken to ensure confidentiality of the data collected.   
Principal Investigator(s)
1. Monique Wasunna
Site(s) in Kenya
1. Kacheliba Kala-azar treatment centre (West Pokot county)
2. Kimalel Health Centre (Baringo county)
 
View

452.

ECCT/11/08/03   Compare the Efficacy and Safety of Gentian Violet to that of Nystatin
    A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings   
Principal Investigator(s)
1. Deborah C Langat
Site(s) in Kenya
1. Kenya Medical Research Institute Walter Reed Project Clinical Research Centre (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

453.

ECCT/11/07/02   REMEMBER
    A5274/REMEMBER "Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. Walter Reed Project (Kericho county)
 
View

454.

ECCT/11/04/01  
    A Double-blind, Randomized Trial of Monthly Treatment with Metronidazole and Miconazole Co-formulated Suppositories versus Placebo for Preventing Vaginal Infections in HIVSeronegative Women (DMID Protocol Number: 09-0070)   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Kenya AIDS Vaccine Initiative (Nairobi City county)
2. Kenya AIDS Control Program (Nairobi City county)
3. Mombasa HIV/STD Research Clinic (Mombasa county)
 
View

455.

ECCT/11/02/01   Compare the Efficacy and Safety of Gentian Violet to that of Nystatin
    A5265 - A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View